Low intensity vibration with zoledronate reduces musculoskeletal weakness and adiposity in estrogen deprived female mice

Authors:

Abstract
Aromatase inhibitors are widely used in the treatment of hormone-sensitive breast cancer, but their suppression of estrogen production accelerates bone loss, increases fracture risk, and negatively impacts muscle and fat metabolism. Here, we demonstrate that daily low intensity vibration, serving as a non-drug mimetic for exercise, protects musculoskeletal health in skeletally immature, female mice under complete estrogen deprivation. Subsequent improvements in vertebral bone density are paralleled by greater and leaner skeletal muscle mass and function alongside reduced fat accretion and circulating metabolites. In mature, estrogen deprived mice, vibration enhances weekly bisphosphonate treatment, improving bone density, cortical thickness, and mechanical resistance to fracture. These findings support the proposed hypothesis that low intensity vibration reduces musculoskeletal frailty in estrogen deprived mice, with stronger effects observed in younger cohorts, while in skeletally mature mice combination therapy with anti-resorptive treatment is necessary to suppress cancer-treatment induced musculoskeletal degradation.
Funding Information
  • Indiana Clinical and Translational Sciences Institute (TL1 TR002531)
  • Indiana Clinical and Translational Sciences Institute (UL1 TR002529)
  • Lawrence Family Bone Disease Program of Texas
  • U.S. Department of War (W81XWH-16-1-0040)
  • U.S. Department of War (BC150678P1)
  • Dive Into The Pink; Indiana University School of Medicine Center for Musculoskeletal Health; Peggy S. Throgmartin Endowment; Lawrence Family Bone Disease Program of Texas

This publication has 108 references indexed in Scilit: